And SSYX administrated significantly down-regulated the TLR4/MyD88/CaMKII signaling pathway induced by MetS, which further validated the role of TLR signaling pathway in the treatment effect of SSYX on MetS-induced VA. The gene discussed is CAMK2G; the disease is metabolic syndrome.